Zoledronic acid – A once-yearly, intravenous dose of zoledronic acid (sample brand name: Reclast) is also available for the treatment of osteoporosis. This medication is given into a vein (by "IV") over 15 minutes and is usually well tolerated.
Zoledronic acid is given once a year as an intravenous (IV) infusion to treat osteoporosis. It is also given every two years as an IV infusion to prevent osteoporosis. Zoledronic acid increases bone density and reduces the incidence of the spine and non-spine fractures, including hip fractures.
Zoledronic acid – Zoledronic acid is a bisphosphonate that is administered as a 30-minute intravenous infusion once yearly.
Bisphosphonates are usually the first choice for osteoporosis treatment. These include: Alendronate (Fosamax), a weekly pill. Risedronate (Actonel), a weekly or monthly pill.
The results of this trial indicate that a once-yearly infusion of zoledronic acid during a 3-year period significantly reduces the risk of vertebral, hip, and other fractures in patients with postmenopausal osteoporosis.
Fever is the most common adverse effect associated with zoledronic acid infusion. Flu-like syndromes including fever, chills, bone pain, and/or arthralgias and myalgias have also occasionally been reported. These symptoms generally did not require treatment and resolved within 24 to 48 hours.
One death (from any cause) is prevented for every 27 patients who received zoledronic acid instead of placebo (NNT = 27; 95% CI, 15.4 to 96.3).
Alendronate (Fosamax™), risedronate (Actonel™, Atelvia™), ibandronate (Boniva™), and zoledronic acid (Reclast™) are all FDA approved for osteoporosis prevention and/or treatment.
Denosumab injection (Prolia) is used
treat osteoporosis that is caused by corticosteroid medications in men and women who will be taking corticosteroid medications for at least 6 months and have an increased risk for fractures or who cannot take or did not respond to other medication treatments for osteoporosis.
Bisphosphonates — Bisphosphonates are medications that slow the breakdown and removal of bone (ie, resorption). They are widely used for the prevention and treatment of osteoporosis in postmenopausal women.
Alendronate, risedronate, and ibandronate have all been shown effective for reducing spine fractures. For women with a history of hip or non-spinal fractures, alendronate and risedronate may be better options than ibandronate.
Bisphosponates such as risedronate (Actonel), alendronate (Fosamax), ibandronate (Boniva), zoledronic acid (Reclast), and pamidronate (Aredia) are used to treat and prevent osteoporosis—or, bone thinning—which occurs when the bones lose calcium and other minerals that help keep them strong and compact.
For bone cancer and multiple myeloma, this medicine is usually given every 3 to 4 weeks. This treatment will continue until your body responds to the medicine. For osteoporosis, this medicine is usually given once a year and will continue until your body responds to the medicine.
This lowers your risk for bone fractures. You'll get Prolia injections from a healthcare professional once every 6 months. The drug stays in your system and continues to slow bone breakdown over this period of time. Every 6 months you'll get another dose of Prolia.
Denosumab is also known by its brand names, Xgeva and Prolia. It helps to prevent fractures and other cancer related bone problems in adults with cancer that has spread to the bones. Prolia can reduce the risk of spinal fractures in men who have weakened bones due to hormone therapy for prostate cancer.
Compared to other osteoporosis treatments, only Prolia® is 1 shot every 6 months. You should take calcium and vitamin D as your doctor tells you to while you receive Prolia®.
Teriparatide is an osteoporosis medication that can help strengthen your bones and reduce your risk of breaking a bone. It is available as a daily injection, which you do yourself. Teriparatide is taken for up to two years. Teriparatide is a parathyroid hormone treatment.
Intraosseous infusion (IO) is the process of injecting medications, fluids, or blood products directly into the marrow of a bone; this provides a non-collapsible entry point into the systemic venous system.
EVENITY® reduced the risk of new spine fractures by 73% vs. placebo at 12 months. This study followed 7,180 women with postmenopausal osteoporosis receiving EVENITY® or placebo (a treatment without medicine) for 12 months.
Bisphosphonates. This is the most commonly used class of medicines to treat osteoporosis in men and women. They work by slowing the rate of bone loss.
In one comparative study of zoledronic acid and denosumab, denosumab showed a greater increase in spinal bone mass density (BMD) compared to zoledronic acid. Zoledronic acid also showed a greater incidence of flu-like symptoms. Based on this study, Prolia may be more effective for certain people.
The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic acid 5 mg. The symptoms are usually mild to moderate and go away within three days.